$1.70
-0.16-8.6%
最終更新: Oct 13, 7:09 PM
$1.68
-0.18-9.75%
Benzinga
Benzinga
Benzinga
火曜日, 10 13
Benzinga
© 2026 Benzinga | All Rights Reserved
ADC Therapeutics (ADCT) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.21 | $-0.20 | $-0.29 | $-0.38 |
| Actual | $-0.11 | $-0.13 | $-0.09 | $-0.19 |
| Surprise | +47.6% | +35.0% | +69.0% | +50.0% |
| Revenue | ||||
| Estimate | $19.1M | $19.9M | $21.0M | $16.5M |
| Actual | $19.2M | $20.9M | $23.1M | $16.4M |
| Surprise | +0.53% | +4.58% | +9.61% | -0.54% |
| Metric | Q3 '26E | Q4 '26E |
|---|---|---|
| Earnings Per Share (Non-GAAP) | ||
| Consensus | $-0.21 | $-0.20 |
| Revenue | ||
| Consensus | $19.4M | $21.6M |
| 会計四半期 | 報告日 | 実質EPS | 推定EPS | 驚き ％ |
|---|---|---|---|---|
| Q2 | Aug 13, 2026 | $-0.11 | $-0.21 | 47.6 % |
| Q1 | May 4, 2026 | $-0.13 | $-0.20 | 35.0 % |
| Q4 | Mar 10, 2026 | $-0.09 | $-0.29 | 69.0 % |
| Q3 | Nov 10, 2025 | $-0.19 | $-0.38 | 50.0 % |
| 会計四半期 | 報告日 | 実際の収益 | 推定収益 | 驚き ％ |
|---|---|---|---|---|
| Q2 | Aug 13, 2026 | $19.25M | $19.15M | 0.53 % |
| Q1 | May 4, 2026 | $20.85M | $19.94M | 4.58 % |
| Q4 | Mar 10, 2026 | $23.06M | $21.04M | 9.61 % |
| Q3 | Nov 10, 2025 | $16.43M | $16.52M | -0.54 % |